{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T02:52:39Z","timestamp":1772160759647,"version":"3.50.1"},"reference-count":26,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2016,3,23]],"date-time":"2016-03-23T00:00:00Z","timestamp":1458691200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Liver International"],"published-print":{"date-parts":[[2016,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background &amp; Aims<\/jats:title>\n                    <jats:p>\n                      In Taiwan, patients with chronic hepatitis C virus (\n                      <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content>\n                      ) infection are currently treated with pegylated interferon\u2010alpha plus ribavirin, but interferon\u2010based regimens can be poorly tolerated, especially by those with advanced liver disease and the elderly. Sofosbuvir, an oral nucleotide analogue inhibitor of\n                      <jats:styled-content style=\"fixed-case\">HCV NS<\/jats:styled-content>\n                      5B polymerase, is approved in Europe, the USA and Japan for treating chronic\n                      <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content>\n                      infection. This phase 3b study examined the efficacy and safety of sofosbuvir plus ribavirin in Taiwanese patients with chronic genotype 2\n                      <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content>\n                      infection \u00b1 compensated cirrhosis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      In this multicentre, open\u2010label, phase 3b (\n                      <jats:styled-content style=\"fixed-case\">NCT<\/jats:styled-content>\n                      02021643) study, 87 patients (\n                      <jats:italic>n<\/jats:italic>\n                      = 43, treatment\u2010naive;\n                      <jats:italic>n<\/jats:italic>\n                      = 44, treatment\u2010experienced) received 12 weeks of treatment with sofosbuvir plus weight\u2010based ribavirin. The primary efficacy endpoint was the proportion of patients with sustained virological response 12 weeks after treatment discontinuation (\n                      <jats:styled-content style=\"fixed-case\">SVR<\/jats:styled-content>\n                      12). Safety and pharmacokinetic data were also collected.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      All 87 patients (100%; 95% confidence interval, 92\u2013100%) achieved\n                      <jats:styled-content style=\"fixed-case\">SVR<\/jats:styled-content>\n                      12, including the 13 patients with compensated cirrhosis. The most common treatment\u2010emergent adverse events (\n                      <jats:styled-content style=\"fixed-case\">AE<\/jats:styled-content>\n                      s) were insomnia (16%, 14\/87) and upper respiratory tract infection (16%, 14\/87). No grade 3 or grade 4\n                      <jats:styled-content style=\"fixed-case\">AE<\/jats:styled-content>\n                      was reported. There was one serious\n                      <jats:styled-content style=\"fixed-case\">AE<\/jats:styled-content>\n                      (biliary colic), which was deemed unrelated to study treatment. Laboratory abnormalities other than ribavirin\u2010related reductions in haemoglobin were uncommon.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      The results from this phase 3b study demonstrate that 12 weeks of treatment with the interferon\u2010free regimen sofosbuvir plus ribavirin is effective and well tolerated in both treatment\u2010naive and treatment\u2010experienced Taiwanese patients with chronic genotype 2\n                      <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content>\n                      infection.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/liv.13082","type":"journal-article","created":{"date-parts":[[2016,2,2]],"date-time":"2016-02-02T09:06:49Z","timestamp":1454404009000},"page":"1101-1107","source":"Crossref","is-referenced-by-count":27,"title":["A phase 3b study of sofosbuvir plus ribavirin in Taiwanese patients with chronic genotype 2 hepatitis C virus infection"],"prefix":"10.1111","volume":"36","author":[{"given":"Jia\u2010Horng","family":"Kao","sequence":"first","affiliation":[{"name":"National Taiwan University College of Medicine and Hospital Taipei Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rong\u2010Nan","family":"Chien","sequence":"additional","affiliation":[{"name":"Liver Research Unit Chang Gung Memorial Hospital\u2010Keelung Keelung Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting\u2010Tsung","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine National Cheng Kung University Hospital Tainan Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng\u2010Yuan","family":"Peng","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine School of Medicine China Medical University Taichung Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsung\u2010Hui","family":"Hu","sequence":"additional","affiliation":[{"name":"Chang Gung Medical Foundation Kaohsiung Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gin\u2010Ho","family":"Lo","sequence":"additional","affiliation":[{"name":"Department of Medicine E\u2010Da Hospital Kaohsiung Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Horng\u2010Yuan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Mackay Memorial Hospital Taipei Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jyh\u2010Jou","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Chi Mei Hospital Liouying Tainan Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jenny C.","family":"Yang","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc. Foster City CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven J.","family":"Knox","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc. Foster City CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lingling","family":"Han","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc. Foster City CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongmei","family":"Mo","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc. Foster City CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anita","family":"Mathias","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc. Foster City CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana M.","family":"Brainard","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc. Foster City CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I\u2010Shyan","family":"Sheen","sequence":"additional","affiliation":[{"name":"Chang Gung Memorial Hospital and Medical College Chang Gung University Taoyuan Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu\u2010Chun","family":"Hsu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology Changhua Christian Hospital Changhua Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chi\u2010Jen","family":"Chu","sequence":"additional","affiliation":[{"name":"Department of Medicine Taipei Veterans General Hospital Taipei Taiwan"},{"name":"School of Medicine National Yang\u2010Ming University Taipei Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wan\u2010Long","family":"Chuang","sequence":"additional","affiliation":[{"name":"Kaohsiung Medical University Hospital Kaohsiung Medical University Kaohsiung Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,3,23]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vhri.2013.08.001"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.29.1500"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jis385"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.2001"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-012-9342-y"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2005.01196.x"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2006.102558"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1086\/650470"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12112"},{"key":"e_1_2_8_11_1","volume-title":"SOVALDI (sofosbuvir) Summary of Product Characteristics","author":"Gilead Sciences International Ltd","year":"2015"},{"key":"e_1_2_8_12_1","volume-title":"SOVALDI (sofosbuvir) Prescribing Information","author":"Gilead Sciences Inc","year":"2014"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12312"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1214853"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1214854"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1316145"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1159\/000180580"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12499"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/biomet\/26.4.404"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v19.i12.1943"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2003.50350"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/gene.2011.1"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1100349108"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature08309"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature08463"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.07.043"},{"key":"e_1_2_8_27_1","volume-title":"Ribavirin (COPEGUS) Prescribing Information","author":"Genentech","year":"2013"}],"container-title":["Liver International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fliv.13082","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/liv.13082","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/liv.13082","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/liv.13082","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T19:42:48Z","timestamp":1695498168000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/liv.13082"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,23]]},"references-count":26,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["10.1111\/liv.13082"],"URL":"https:\/\/doi.org\/10.1111\/liv.13082","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.726114217.793514301","asserted-by":"object"}]},"ISSN":["1478-3223","1478-3231"],"issn-type":[{"value":"1478-3223","type":"print"},{"value":"1478-3231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,23]]}}}